Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
8617689
Reference Type
Journal Article
Title
Immune reactivity during COVID-19: Implications for treatment
Author(s)
Napoli, C; Benincasa, G; Criscuolo, C; Faenza, M; Liberato, C; Rusciano, M
Year
2021
Is Peer Reviewed?
Yes
Journal
Immunology Letters
ISSN:
0165-2478
EISSN:
1879-0542
Volume
231
Page Numbers
28-34
Language
English
DOI
10.1016/j.imlet.2021.01.001
URL
https://www.proquest.com/scholarly-journals/immune-reactivity-during-covid-19-implications/docview/2476559544/se-2?accountid=171501
Exit
Abstract
Clinical symptoms of COVID-19 include fever, cough, and fatigue which may progress to acute respiratory distress syndrome (ARDS). The main hematological laboratory findings associated with the severe form of disease are represented by lymphopenia and eosinopenia which mostly occur in the elderly population characterized by cardiovascular comorbidities and immunosenescence. Besides, increased levels of D-dimer, procalcitonin, and C reactive protein (CRP) seem to be powerful prognostic biomarkers helping to predict the onset of coagulopathy. The host immune response to SARS-CoV-2 can lead to an aberrant inflammatory response or "cytokine storm" which contributes to the severity of illness. At immunological level, patients affected by a severe form of COVID-19 show poor clinical trajectories characterized by differential "immunotypes" for which T cell response seems to play a critical role in understanding pathogenic mechanisms of disease. Also, patients with mild to severe COVID-19 displayed macrophage activation syndrome (MAS), very low human leukocyte antigen D related (HLA-DR) expression with a parallel reduction of CD04+ lymphocytes, CD19 lymphocytes, and natural killer (NK) cells. Corticosteroids resulted the best therapy for the immune dysregulation whereas repurposing of tocilizumab (IL-6 receptor antagonist) appears to have mixed results in patients with COVID-19. Besides, anticoagulative therapy was associated with reduced in-hospital mortality and need of intubation among COVID-19 patients. Furthermore, the beneficial use of intravenous immunoglobulin (IVIG) and passive immunotherapy with convalescent plasma needs to be validated in large controlled clinical trials. In this review, we summarize the main hematological parameters with a prognostic value in COVID-19 and the basis of immunological reactivity during COVID-19, with a focus on ongoing clinical trials evaluating immune targets as possible therapeutic strategies.
Keywords
Antibodies, Monoclonal, Humanized; Anticoagulants; Glucocorticoids; Immunoglobulins, Intravenous; Immunosuppressive Agents; tocilizumab; I031V2H011; Index Medicus; COVID-19; drug therapy; immune response; laboratory indexes; Glucocorticoids -- therapeutic use; Severity of Illness Index; Prognosis; Hospital Mortality; Immunoglobulins, Intravenous -- therapeutic use; Treatment Outcome; Drug Repositioning; Antibodies, Monoclonal, Humanized -- therapeutic use; Randomized Controlled Trials as Topic; Anticoagulants -- therapeutic use; Immunization, Passive -- methods; Drug Therapy, Combination -- methods; Immunosuppressive Agents -- therapeutic use; SARS-CoV-2 -- immunology; Cytokine Release Syndrome -- prevention & control; Immunotherapy -- methods; SARS-CoV-2 -- isolation & purification; COVID-19 -- complications; COVID-19 -- diagnosis; COVID-19 -- immunology; Cytokine Release Syndrome -- immunology; COVID-19 -- drug therapy; COVID-19 -- therapy
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity